JPS6128645B2 - - Google Patents
Info
- Publication number
- JPS6128645B2 JPS6128645B2 JP48094268A JP9426873A JPS6128645B2 JP S6128645 B2 JPS6128645 B2 JP S6128645B2 JP 48094268 A JP48094268 A JP 48094268A JP 9426873 A JP9426873 A JP 9426873A JP S6128645 B2 JPS6128645 B2 JP S6128645B2
- Authority
- JP
- Japan
- Prior art keywords
- collagen
- skin
- soluble
- acid
- procollagen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 108010035532 Collagen Proteins 0.000 claims description 37
- 102000008186 Collagen Human genes 0.000 claims description 37
- 229920001436 collagen Polymers 0.000 claims description 37
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 29
- 239000000243 solution Substances 0.000 claims description 16
- 239000011780 sodium chloride Substances 0.000 claims description 15
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 10
- 210000002808 connective tissue Anatomy 0.000 claims description 10
- 230000007935 neutral effect Effects 0.000 claims description 10
- 239000002243 precursor Substances 0.000 claims description 8
- 230000009471 action Effects 0.000 claims description 5
- 239000011668 ascorbic acid Substances 0.000 claims description 5
- 229960005070 ascorbic acid Drugs 0.000 claims description 5
- 235000010323 ascorbic acid Nutrition 0.000 claims description 5
- 239000002244 precipitate Substances 0.000 claims description 4
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims description 3
- 229910052921 ammonium sulfate Inorganic materials 0.000 claims description 3
- 235000011130 ammonium sulphate Nutrition 0.000 claims description 3
- 230000000087 stabilizing effect Effects 0.000 claims description 3
- 239000007853 buffer solution Substances 0.000 claims description 2
- 238000000502 dialysis Methods 0.000 claims description 2
- 239000013543 active substance Substances 0.000 claims 2
- 238000004090 dissolution Methods 0.000 claims 1
- 238000004108 freeze drying Methods 0.000 claims 1
- 239000011814 protection agent Substances 0.000 claims 1
- 238000009738 saturating Methods 0.000 claims 1
- 210000003491 skin Anatomy 0.000 description 26
- 239000000284 extract Substances 0.000 description 21
- 108010050808 Procollagen Proteins 0.000 description 17
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 239000002253 acid Substances 0.000 description 8
- 238000005119 centrifugation Methods 0.000 description 7
- 239000003755 preservative agent Substances 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 108010010803 Gelatin Proteins 0.000 description 5
- 229920000159 gelatin Polymers 0.000 description 5
- 239000008273 gelatin Substances 0.000 description 5
- 235000019322 gelatine Nutrition 0.000 description 5
- 235000011852 gelatine desserts Nutrition 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 230000002335 preservative effect Effects 0.000 description 5
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 229960002591 hydroxyproline Drugs 0.000 description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
- 150000007524 organic acids Chemical class 0.000 description 4
- 210000002826 placenta Anatomy 0.000 description 4
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 4
- 108010077465 Tropocollagen Proteins 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 239000010692 aromatic oil Substances 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000003169 placental effect Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 2
- 238000010306 acid treatment Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- SASYSVUEVMOWPL-NXVVXOECSA-N decyl oleate Chemical compound CCCCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC SASYSVUEVMOWPL-NXVVXOECSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 210000002741 palatine tonsil Anatomy 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000003009 skin protective agent Substances 0.000 description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 241000283080 Proboscidea <mammal> Species 0.000 description 1
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical compound ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000001166 ammonium sulphate Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 230000036570 collagen biosynthesis Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 210000001608 connective tissue cell Anatomy 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 102000034240 fibrous proteins Human genes 0.000 description 1
- 108091005899 fibrous proteins Proteins 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000008571 general function Effects 0.000 description 1
- 239000008169 grapeseed oil Substances 0.000 description 1
- QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000012177 spermaceti Substances 0.000 description 1
- 229940084106 spermaceti Drugs 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000002522 swelling effect Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 230000007838 tissue remodeling Effects 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045860 white wax Drugs 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
- A61K8/982—Reproductive organs; Embryos, Eggs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Description
本発明は、再活性化作用を有する皮膚保護剤に
関する。
周知のように、皮膚の主要な老化現象は結合組
織(真皮)で組織の改造の形で生じる。保護組織
及び結合組織の主要成分はいわゆるコラーゲンで
あり、これは繊維状硬蛋白質の蛋白質群の包括名
称として使用される。皮膚の老化現象の間にコラ
ーゲンを含有する繊維は、その構造を、先づ架橋
しないで存在する繊維が年令と共に増大する分子
間又は分子内の横の架橋を蒙むることによつて変
える。繊維の著しい架橋に基づいて皮膚の水の結
合力は低下するので、皮膚はその膨潤性を失い、
非弾性になる。皮膚は老化し、増大したしわを形
成する傾向を有する。
ドイツ特許第1194098号明細書からは、コラー
ゲンから得られた一定の性質のゼラチンを、化粧
用調剤として皮膚の膨張を改良するために使用す
ることは公知である。この調剤を用いて皮膚の水
の結合力が改良される。ゼラチンは、動物の皮の
酸性加水分解によつて得られる。
最後に、皮膚の弾性の十分な増大はドイツ公開
特許第2064604号明細書の目的であり、このため
にはこの明細書に皮膚保護剤が記載されており、
これは十分に非架橋の変らないコラーゲン構造を
有する可溶性の天然のコラーゲンを含有する。可
溶性の天然のコラーゲンは、若い及び/又は胎児
の動物の皮から結合組織からの直接的抽出によつ
て得られる。抽出は、穏和な方法で弱酸性水媒体
中で有機酸及び有機塩を添加して低温度で行なう
ので、コラーゲンの構造は変らない。この物質の
皮膚保護剤の混合成分としての使用は、皮膚の可
溶性コラーゲンの減少をくい止めるか又は可溶性
コラーゲンの損失を補償することができる。
しかしながら試験によつて、コラーゲンから得
られたゼラチンも酸処理によつて抽出したコラー
ゲンも所望の作用を惹起するのには不適当である
ことが判明した。それというのも酸に可溶のコラ
ーゲン並びにコラーゲンのゼラチンは、既に一定
の老化の度合を有するからである。この外に、酸
に可溶のコラーゲンは一般に天然のコラーゲンの
組織では極めてわずかな成分に変るのに過ぎず、
それ故少くともこの方法では皮膚の可溶性コラー
ゲンの損失の補償は不可能であることが立証され
た。
ところで、天然のコラーゲンの中性塩に可溶の
前駆物質は、純粋の形で並びに混合成分として優
れた方法で化粧用及び皮膚の保護に適当であるこ
とが判明した。
周知のように、コラーゲンの形成は繊維芽細胞
中で行われる。基礎構成物質はいわゆるトロポコ
ラーゲンであり、これは時の経つうちに重合して
天然のコラーゲンを形成する。新たに形成したト
ロポコラーゲンは細胞外コラーゲンの最早期の形
と考えられ、それ故これと共に同時にコラーゲン
を形成するための化学的基礎構成物質を補給する
ことによつて、もはやコラーゲンを形成すること
のできない老化細胞を活性化するのに特に適当で
ある。実施した実験について、この方法の範囲内
で活性化された結合組織の細胞は、新しい機能を
有するコラーゲンを生じ得ることが立証された。
結合組織の構造の好ましい調整は、天然のコラ
ーゲンの前記前駆物質を後から酸の添加によつて
安定にすると、なお増大することができる。この
ためには、好ましくはアスコルビン酸を使用する
ことができる。これはコラーゲンの生合成で重要
である。
最後に、天然のコラーゲンの中性塩に可溶の前
駆物質と水溶性胎盤抽出物との混合物は、特に好
ましいことが立証された。後に挙げた実施例につ
いてなお詳説するように、既に中性塩に可溶の抽
出物と胎盤抽出物との1:1の混合割合は付加的
陽性作用を示す。使用した胎盤抽出物は3〜7ケ
月の胎盤から製出する。
アイソトープの方法によつて、中性塩に可溶の
抽出物は、天然のコラーゲンに対する直接的前駆
物質であることが立証された。更に、中性塩の溶
解性は年令が大きくなるにつれて減少する中性塩
に可溶の前駆物質は、アルフア連鎖90%とベータ
連鎖10%とからなり、アルフア連鎖が後から組織
中で変換した天然のコラーゲンになるのに過ぎな
いことが立証された。それ故、天然のコラーゲン
は、トロポコラーゲンの構成物質から大きい単位
を形成して生じるので、既に新たに形成した天然
のコラーゲンは或る程度架橋した繊維構造を有す
る。前記前駆物質とは異なり、天然のコラーゲン
は少くとも若い結合組織では或る程度まで酸に可
溶である。酸の溶解性は架橋が増すにつれて著し
く減少する。
試験によつて、酸処理により得られたコラーゲ
ンは極めてわずかな割合のアルフア連鎖を有する
ので、この理由から酸に可溶のフラクシヨンを、
結合組織を活性化させるために使用することは、
好結果を得ることはできないことが判明した。
次になおいわゆるプロコラーゲンと呼ばれるの
に過ぎない天然のコラーゲンに対する前記前駆物
質は、未生、新生又は死生の哺乳動物の胎児の結
合組織(皮、腱、軟骨、骨)から中性塩の処理に
よつて抽出することができる。この動物の例とし
ては、次のものが挙げられる:仔牛、仔豚、らく
だ、象その他。
中性塩の処理はNaClの作用であり、その際
NaClの濃度は好ましくは緩衝溶液中で0.01〜10
モルである。続く沈殿は、濃NaCl溶液でか又は
硫酸アンモニウムを飽和させることによつて行な
う。塩に可溶のプロコラーゲンは、冷凍乾燥及
び/又は有機酸、例えばアスコルビン酸、クエン
酸又はCH3(CH2)o・COOH〔n=0,1,2,
3〕系の酸の0.1〜0.3N−溶液中で保持する。
摩砕した動物の原料の抽出開始に対してはでき
るだけ早く、保存剤並びに浸透剤を添加するのが
望ましい。保存剤としては、例えばトルオール又
はニパギン(Nipagine)が役立つ。
得られた溶液の判定は、その蛋白質、ヒドロキ
シプロリン及びヒドロキシリシンの含量に基づい
て行なう。
キエルダールの測定から、一般に0.3〜0.6%で
存在する蛋白質含量が得られる。純粋のプロコラ
ーゲンのヒドロキシプロリン含量は、13〜14%で
ある。
次に実施例につきプロコラーゲン抽出物の製出
を説明する。
例 1
摩砕した仔牛の皮50Kgを、0.02M−燐酸塩を緩
衝させた6〜11倍の量の0.1〜0.5M−NaCl溶液で
2回12〜48時間抽出した。使用した緩衝液は
KH2PO4−NaOHからなつていた。遠心分離−始
終温度0℃で−後に、固体NaClを濃度15〜22%
まで添加した。放置し、0℃で撹拌した後に、
3000〜6000rpmで遠心分離し、沈殿物をニパギン
調剤0.1%を含有する5〜10倍の量の0.05M−酢
酸中で撹拌し、更に0℃で長時間遠心分離後、燐
酸塩緩衝液を添加してPH7.4にした0.5M−NaCl溶
液に対して透析した。固体NaClを濃度15〜20%
で添加した後、沈殿したプロコラーゲンを遠心分
離して取出し、0.1〜0.3Mのクエン酸、酢酸、ア
スコルビン酸に溶解し、場合により相応する酸溶
液に対して数回透析し、遠心分離した。適当なニ
パギン調剤、トウイーン(Tween)−80及びプロ
ピレングリコールを添加して、保存し得る最終生
成物を製出した。分析によつてN0.6%及び理論
値のヒドロキシプロリンが得られた。
例 2
血液、肉、及び脂肪を除去した後に、豚の胎児
の皮20Kgをひき肉機で摩砕し、5倍の量の10%の
NaCl溶液で3℃で4回数日間抽出した。トリオ
ール又はニパギンを添加して細菌の作用を防止し
た。遠心分離後、溶液に温度に応じて硫酸アンモ
ニウム55〜75%を飽和させ、沈殿物を遠心分離し
て取出した。溶液の密度に応じて遠心分離器の下
方又は上方で取出すことのできる沈殿物を水で洗
浄し、更に遠心分離し、0.5Mの酢酸、クエン酸
に溶解した。遠心分離後、0.5M−NaClに対して
透析した。全操作はできるだけ低温度で行なう。
NaCl10〜13%を添加してプロコラーゲンを沈殿
させ、続いて一定成分のアスコルビン酸、ニパギ
ン調剤、トウイーン−80及びプロピレングリコー
ルを含有する0.1〜0.4M−有機酸溶液に溶解し、
遠心分離する。分析値:コラーゲン中に蛋白質
0.4%及びヒドロキシプロリン14%。
例 3
胎内の哺乳動物の結合組織を、0.5M−NaCl溶
液でPH7.1及び1℃で5回15〜42時間抽出し、遠
心分離する。NaClの添加後、更に遠心分離し、
残渣を0.05M−有機酸に溶解する。酸溶液は0.1M
−NaCl溶液に対して計算量の酸を添加して調製
し、これは結合組織の第2の抽出にPH7.1で使用
する。この抽出物は大量のムコ多糖類を含有し、
これは皮膚の水の結合力に重要である。
本発明による生成物は、例えば次の調剤(クリ
ーム)に混入した(油/水エマルジヨン):
例 :
ラネツテ(Lanette)N 150g
セチオール(Cetiol)V 100g
扁桃油 100g
グリセリン 50g
水 500g
プロコラーゲン抽出物 100g
これに保存剤+芳香油
例 :
ラネツテ(Lanette)N 120g
セチオール(Cetiol)V 80g
密ロウホワイト 60g
ワセリン 10g
パラフイン油 100g
イソリノール酸エステル 5g
ビタミンE 2g
ホラギイノール油溶液 2g
保存剤 2g
水 390g
保存剤 2g
グリセリン 120g
プロコラーゲン抽出物 100g
芳香油 10g
例 :
セラモール(Ceramol) 130g
扁桃油(芳香) 60g
鯨ロウ 10g
セチル/ステリルアルコール 40g
ラノリン 20g
保存剤 2g
グリセリン 50g
水 635g
プロコラーゲン抽出物 50g
芳香油 3g
例 :
ラネツテ(Lanette)N 125g
ブドウの種子油 100g
オレイルアルコール 10g
保存剤 2g
セチルアルコール 5g
プロピレングリコール 50g
クエン酸 5g
水 605g
胎盤抽出物 50g
プロコラーゲン抽出物 50g
例から明らかなように、試料及びはプロコ
ラーゲン抽出物それぞれ100g、試料及びは
プロコラーゲン抽出物それぞれ50gを含有し、そ
の際試料にはなお付加的に胎盤抽出物50gを添
加した。
本発明による生成物の作用を試験するために、
次表による比較試験を行なつた。その際表中で1
で示される試料は、前記プロコラーゲン抽出物の
量又は胎盤抽出物の量の代りに水を含有し、2で
示される試料における前記プロコラーゲン抽出物
の量は、酸の可溶のコラーゲン調剤に代えるよう
にして操作した。最後に、3によつて示される試
験系列では該当するプロコラーゲン抽出物の量
を、相応する量のコラーゲンのゼラチンに代え
た。
TECHNICAL FIELD The present invention relates to a skin protective agent having a reactivating effect. As is well known, the main aging phenomenon of the skin occurs in the form of tissue remodeling in the connective tissue (dermis). The main component of protective and connective tissue is the so-called collagen, which is used as an umbrella name for the fibrous scleroprotein group of proteins. During the aging process of the skin, collagen-containing fibers change their structure in such a way that the initially uncrosslinked fibers undergo inter- or intramolecular lateral cross-linking, which increases with age. Due to significant cross-linking of the fibers, the water binding power of the skin decreases, so the skin loses its swelling properties and
Becomes inelastic. Skin ages and has a tendency to form increased wrinkles. It is known from German Patent No. 1 194 098 that certain properties of gelatin derived from collagen can be used as cosmetic preparations to improve the swelling of the skin. With this preparation the water binding capacity of the skin is improved. Gelatin is obtained by acidic hydrolysis of animal skin. Finally, a sufficient increase in the elasticity of the skin is the aim of German Published Patent Application No. 2064604, and for this purpose skin protective agents are described therein.
It contains soluble natural collagen with a fully uncrosslinked and unaltered collagen structure. Soluble natural collagen is obtained by direct extraction of connective tissue from the skin of young and/or fetal animals. The extraction is carried out in a mild manner in a weakly acidic aqueous medium with the addition of organic acids and organic salts at low temperatures, so that the structure of the collagen remains unchanged. The use of this substance as a mixed component of a skin protectant can reverse the depletion of soluble collagen in the skin or compensate for the loss of soluble collagen. However, tests have shown that neither gelatin obtained from collagen nor collagen extracted by acid treatment are unsuitable for producing the desired effect. This is because acid-soluble collagen and collagen gelatin already have a certain degree of aging. In addition, acid-soluble collagen is generally only a very small component in natural collagen tissue.
It has therefore been established that, at least with this method, it is not possible to compensate for the loss of soluble collagen in the skin. Now, it has been found that the neutral salt-soluble precursors of natural collagen are suitable in an excellent manner for cosmetic and skin protection purposes both in pure form and as a mixed component. As is well known, collagen formation takes place in fibroblasts. The basic constituent is the so-called tropocollagen, which polymerizes over time to form natural collagen. Newly formed tropocollagen is considered to be the earliest form of extracellular collagen, and therefore by simultaneously supplementing it with the chemical building blocks for collagen formation, it is no longer possible to form collagen. It is particularly suitable for activating senescent cells that are unable to function. For the experiments carried out, it was established that the connective tissue cells activated within this method are able to give rise to collagen with new functions. The favorable adjustment of the structure of the connective tissue can be further increased if the precursors of natural collagen are subsequently stabilized by the addition of acids. For this purpose, ascorbic acid can preferably be used. This is important in collagen biosynthesis. Finally, mixtures of neutral salt-soluble precursors of natural collagen and water-soluble placental extracts have proven to be particularly preferred. As will be explained in more detail in the examples given below, a 1:1 mixing ratio of extracts already soluble in neutral salts and placental extracts shows an additive positive effect. The placenta extract used is prepared from 3-7 month old placentas. By isotopic methods, the neutral salt soluble extract was demonstrated to be a direct precursor to natural collagen. Furthermore, the solubility of neutral salts decreases with increasing age.The precursors soluble in neutral salts are composed of 90% alpha chains and 10% beta chains, which are later converted in tissues. It has been proven that this is nothing more than natural collagen. Therefore, since natural collagen originates in large units from the constituents of tropocollagen, the newly formed natural collagen already has a somewhat cross-linked fibrous structure. Unlike the precursors, natural collagen is acid soluble to some extent, at least in young connective tissue. Acid solubility decreases significantly as crosslinking increases. Tests have shown that collagen obtained by acid treatment has a very small proportion of alpha chains, and for this reason the acid-soluble fraction is
It can be used to activate connective tissue.
It turned out that good results could not be obtained. Said precursor to natural collagen, then still only the so-called procollagen, is obtained from the connective tissue (skin, tendon, cartilage, bone) of an unborn, newborn or dead mammalian fetus by the treatment of neutral salts. It can be extracted by Examples of such animals include: calves, piglets, camels, elephants, and others. The treatment of neutral salts is the action of NaCl, in which
The concentration of NaCl is preferably 0.01-10 in the buffer solution
It is a mole. Subsequent precipitation is carried out with concentrated NaCl solution or by saturation with ammonium sulphate. Salt-soluble procollagen can be freeze-dried and/or treated with organic acids such as ascorbic acid, citric acid or CH 3 (CH 2 ) o ·COOH [n=0, 1, 2,
3] Maintain the system in a 0.1-0.3N solution of acid. It is desirable to add preservatives and penetrants as soon as possible to begin extraction of the ground animal material. As preservatives, for example toluol or Nipagine are useful. The resulting solution is evaluated based on its protein, hydroxyproline and hydroxylysine content. Kjeldahl measurements give a protein content which is generally present at 0.3-0.6%. The hydroxyproline content of pure procollagen is 13-14%. Next, the production of procollagen extract will be explained with reference to Examples. Example 1 50 kg of ground calf skin was extracted twice for 12-48 hours with 6-11 times the volume of 0.1-0.5M NaCl solution buffered with 0.02M phosphate. The buffer used was
It consisted of KH 2 PO 4 −NaOH. After centrifugation - at an initial and final temperature of 0°C - solid NaCl was added at a concentration of 15-22%.
Added up to. After standing and stirring at 0°C,
Centrifuge at 3000-6000 rpm, stir the precipitate in 5-10 times the volume of 0.05M acetic acid containing 0.1% Nipagin preparation, and after further centrifugation at 0°C for a long time, add phosphate buffer. Dialysis was performed against a 0.5M NaCl solution adjusted to pH 7.4. Solid NaCl concentration 15-20%
After addition, the precipitated procollagen was removed by centrifugation, dissolved in 0.1-0.3M citric acid, acetic acid, ascorbic acid, optionally dialyzed several times against the corresponding acid solution, and centrifuged. The appropriate Nipagin formulation, Tween-80 and propylene glycol were added to produce a shelf-stable final product. Analysis yielded 0.6% N and theoretical hydroxyproline. Example 2 After removing blood, meat, and fat, grind 20 kg of fetal pig skin in a meat grinder and grind 10% of the 5 times the amount.
Extracted with NaCl solution for 4 times at 3°C. Triol or Nipagin was added to prevent bacterial action. After centrifugation, the solution was saturated with 55-75% ammonium sulfate depending on temperature, and the precipitate was removed by centrifugation. The precipitate, which can be removed at the bottom or top of the centrifuge depending on the density of the solution, was washed with water, further centrifuged and dissolved in 0.5M acetic acid, citric acid. After centrifugation, it was dialyzed against 0.5M-NaCl. All operations are carried out at as low a temperature as possible.
Procollagen is precipitated by adding 10-13% NaCl and subsequently dissolved in a 0.1-0.4M organic acid solution containing the following components ascorbic acid, Nipagin preparation, Tween-80 and propylene glycol;
Centrifuge. Analysis value: Protein in collagen
0.4% and hydroxyproline 14%. Example 3 In utero mammalian connective tissue is extracted with 0.5M NaCl solution at PH7.1 and 1° C. for 5 times for 15-42 hours and centrifuged. After addition of NaCl, further centrifugation
Dissolve the residue in 0.05M organic acid. Acid solution is 0.1M
- Prepared by adding the calculated amount of acid to the NaCl solution, which is used for the second extraction of connective tissue at PH 7.1. This extract contains large amounts of mucopolysaccharides,
This is important for the water binding capacity of the skin. The product according to the invention is incorporated (oil/water emulsion) into, for example, the following preparations (creams): Example: Lanette N 150 g Cetiol V 100 g Tonsil oil 100 g Glycerin 50 g Water 500 g Procollagen extract 100 g Preservative + aromatic oil example: Lanette N 120g Cetiol V 80g White wax 60g Vaseline 10g Paraffin oil 100g Isolinolate ester 5g Vitamin E 2g Holagiinol oil solution 2g Preservative 2g Water 390g Preservative 2g Glycerin 120g procollagen extract 100g aromatic oil 10g Example: Ceramol 130g tonsil oil (fragrant) 60g spermaceti 10g cetyl/steryl alcohol 40g lanolin 20g preservative 2g glycerin 50g water 635g procollagen extract 50g aromatic oil 3g Example: Lanette N 125g Grape seed oil 100g Oleyl alcohol 10g Preservative 2g Cetyl alcohol 5g Propylene glycol 50g Citric acid 5g Water 605g Placenta extract 50g Procollagen extract 50g As is clear from the examples, samples and procollagen extracts Each sample contained 100 g of sample and 50 g of procollagen extract, with 50 g of placenta extract also being added to the sample. To test the action of the products according to the invention,
A comparative test was conducted according to the table below. At that time, 1 in the table
The sample designated 2 contains water in place of the amount of procollagen extract or the amount of placental extract, and the amount of procollagen extract in the sample designated 2 is greater than the amount of procollagen extract in the acid soluble collagen preparation. I operated it by replacing it. Finally, in the test series designated by 3, the amount of the relevant procollagen extract was replaced by the corresponding amount of collagen gelatin.
【表】【table】
【表】
皮膚の毛管の一般的作用は、医学用電子皮膚温
度計を用いる温度の測定によつて判定することが
できる。年令40〜60才の被験者の乾燥した血液の
循環の悪い皮膚では、妨げられた毛管の作用に相
応して著しく変動する皮膚の温度が見出される
(表の第1欄参照)。
油/水エマルジヨン〜及び相応する比較試
料を3週間使用した後に、プロコラーゲン抽出物
を有する試料(,,,)が皮膚に対する
安定化の影響を示したのに過ぎず、これは皮膚の
温度の数日間にわたる安定性によつて認められた
(表の第3欄参照)。
これに反して、相応する比較試料1〜3,1
〜3,1及び1は殆んど安定化作用を示さな
かつた。使用後、依然として皮膚の温度の著しい
変動が確認され、これは皮膚の毛管の作用の改良
が生じないことを示す。
すべての試料は、被験者それぞれ40人について
試験した。Table: The general function of the skin's capillaries can be determined by measuring the temperature using a medical electronic skin thermometer. In the dry, poorly circulatory skin of test subjects between the ages of 40 and 60, a markedly fluctuating skin temperature is found, corresponding to the blocked capillary action (see column 1 of the table). After 3 weeks of use of the oil/water emulsion ~ and the corresponding comparison sample, the sample with procollagen extract (,,,) only showed a stabilizing effect on the skin, which was due to the change in skin temperature. This was confirmed by stability over several days (see column 3 of the table). On the contrary, the corresponding comparison samples 1-3 , 1
-3 , 1 and 1 showed almost no stabilizing effect. After use, significant fluctuations in the temperature of the skin are still observed, indicating that no improvement in the action of the skin capillaries occurs. All samples were tested on 40 subjects each.
【表】【table】
【表】
ン (1)−(3)
(1) (2) (3) (
4)
[Table] N (1)−(3)
(one two three) (
Four)
Claims (1)
コラーゲンを含有する皮膚保護剤において、作用
物質は、結合組織から中性緩衝溶液中で食塩で抽
出し、続いて濃塩化ナトリウム溶液で沈殿させる
か又は硫酸アンモニウムを飽和させ、遠心分離し
て製造し、沈殿物を冷凍乾燥及び/又は0.1〜
0.3N−アスコルビン酸溶液に溶解して安定に
し、その際溶解の前又は後に透析することによる
天然のコラーゲンの中性塩に可溶の前駆物質から
なる皮膚保護剤。1. In skin protection agents with reactivating action and containing soluble collagen as active substance, the active substance is extracted from the connective tissue with sodium chloride in a neutral buffer solution and subsequently precipitated with concentrated sodium chloride solution. Or prepare by saturating ammonium sulfate, centrifuging, freeze-drying the precipitate and/or
A skin protectant consisting of a neutral salt-soluble precursor of natural collagen by stabilizing it by dissolving it in a 0.3N ascorbic acid solution and dialysis before or after dissolution.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE2321306A DE2321306C2 (en) | 1973-04-27 | 1973-04-27 | Skin care products |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS49134816A JPS49134816A (en) | 1974-12-25 |
JPS6128645B2 true JPS6128645B2 (en) | 1986-07-01 |
Family
ID=5879411
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP48094268A Expired JPS6128645B2 (en) | 1973-04-27 | 1973-08-22 |
Country Status (2)
Country | Link |
---|---|
JP (1) | JPS6128645B2 (en) |
DE (1) | DE2321306C2 (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6019725B2 (en) * | 1977-10-04 | 1985-05-17 | ポ−ラ化成工業株式会社 | skin cosmetics |
JPS5865208A (en) * | 1981-10-12 | 1983-04-18 | Asahi Denka Kogyo Kk | Cosmetic |
FR2611495A1 (en) * | 1987-02-24 | 1988-09-09 | Cochand Georges | Cosmetological product intended for application to the skin |
JPH0781139B2 (en) * | 1987-04-09 | 1995-08-30 | 株式会社コーセー | Antioxidant composition |
FR2613620B1 (en) * | 1987-04-13 | 1991-04-19 | Krom Robert | IMPLANT FOR HUMAN MEDICINE |
JP2769321B2 (en) * | 1988-03-18 | 1998-06-25 | 三省製薬株式会社 | External preparation |
JP2769341B2 (en) * | 1988-12-28 | 1998-06-25 | 三省製薬株式会社 | Stable external base composition |
JP2808307B2 (en) * | 1989-06-29 | 1998-10-08 | ポーラ化成工業株式会社 | External preparation for skin |
JP2799881B2 (en) * | 1989-06-29 | 1998-09-21 | ポーラ化成工業株式会社 | Makeup cosmetics |
EP2664341A3 (en) * | 2006-10-06 | 2014-01-08 | Anthrogenesis Corporation | Native (telopeptide) placental collagen compositions |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2064604C3 (en) * | 1970-12-30 | 1982-10-21 | Chemisches Laboratorium Dr. Kurt Richter Gmbh, 1000 Berlin | Skin care products |
-
1973
- 1973-04-27 DE DE2321306A patent/DE2321306C2/en not_active Expired
- 1973-08-22 JP JP48094268A patent/JPS6128645B2/ja not_active Expired
Also Published As
Publication number | Publication date |
---|---|
DE2321306A1 (en) | 1974-11-14 |
JPS49134816A (en) | 1974-12-25 |
DE2321306C2 (en) | 1988-08-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US3991184A (en) | Agent for the care of skin | |
US3794561A (en) | Biologically active peptide and method of preparing the same | |
US4451397A (en) | Method of preparing collagen products | |
JPH08231370A (en) | Skin cosmetic | |
CN103547254B (en) | Containing the wrinkle improvement compositions from the composition of Placenta Hominis | |
US4503047A (en) | Compositions for stimulating keratin formation in hair bulbs employing horseradish and mustard seed extracts | |
JPS6128645B2 (en) | ||
US5698185A (en) | Whitening cosmetic preparation and method of using same | |
EP0182756A2 (en) | Dermotropic cosmetic compositions | |
DE2625289A1 (en) | PROCESS FOR MANUFACTURING A STERILE COLLAGEN PRODUCT WITH FELT OR. FLEECE-LIKE FIBER STRUCTURE | |
JPS59130207A (en) | Corium and hair growth promoting cosmetic composition | |
GB721312A (en) | Improvements in or relating to the formation of fibrous protein from solutions of collagen | |
JPH04503807A (en) | Cosmetic composition for hair containing glycoprotein | |
JP3342050B2 (en) | Cosmetics | |
JP2533376B2 (en) | Skin cosmetics | |
JPS6064908A (en) | Cosmetic | |
Heikkinen et al. | Collagen components in the consecutive extracts of rat skin | |
JP2769341B2 (en) | Stable external base composition | |
JPH03255014A (en) | Cosmetic | |
JPH01246208A (en) | External use preparation for skin | |
JP3272892B2 (en) | Method for insolubilizing soluble keratin, method for modifying hair, and hair modifying agent | |
JPS62215516A (en) | Hair tonic and skin cosmetic | |
JPS58177918A (en) | Inhibitor for melanin formation by placental decomposition product | |
GB866509A (en) | Therapeutic agent prepared from brain tissues and the preparation of such agent | |
JP3168128B2 (en) | Method for insolubilizing soluble keratin, hair modifying agent and hair modifying method |